These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35899664)

  • 1. [Évolution des traitements adjuvants des cancers de l'ovaire].
    Pautier P
    Rev Prat; 2022 Jun; 72(6):633-637. PubMed ID: 35899664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer.
    Pierre ME; Manneh R; Hernández A; Rodríguez J; Fletcher AV; Ramírez HM; Niño OM; Gómez DA; Sanabria D; Contreras F; Pieschacón JR; Calderón PH
    Rev Colomb Obstet Ginecol; 2024 Jun; 75(1):. PubMed ID: 39013199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Traitement médical de première ligne du cancer épithélial de l'ovaire de haut grade: First-line medical treatment of high-grade epithelial ovarian cancer.
    Selle F; Alexandre J; Prulhière K; Kalbacher E; Ray-Coquard I; Leary A;
    Bull Cancer; 2021 Dec; 108(9S1):S5-S12. PubMed ID: 34955161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prise en charge médicale de la récidive du cancer épithélial de l'ovaire: Medical management of recurrent epithelial ovarian cancer.
    Pautier P; Motte-Rouge T; Lécuru F; Classe JM; Ferron G; Floquet A; Kurtz JE; Freyer G; Hardy-Bessard AC
    Bull Cancer; 2021 Dec; 108(9S1):S22-S32. PubMed ID: 34955159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current post-surgical treatment strategies in first-line ovarian cancer].
    Ouali K; Michels J; Blanc-Durand F; Leary A; Kfoury M; Genestie C; Morice P; Zaccarini F; Scherrier S; Gouy S; Maulard A; Pautier P
    Bull Cancer; 2024 Mar; 111(3):267-276. PubMed ID: 36863923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States.
    Penn CA; Wong MS; Walsh CS
    JAMA Netw Open; 2020 Dec; 3(12):e2028620. PubMed ID: 33295974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
    Harter P; Mouret-Reynier MA; Pignata S; Cropet C; González-Martín A; Bogner G; Fujiwara K; Vergote I; Colombo N; Nøttrup TJ; Floquet A; El-Balat A; Scambia G; Guerra Alia EM; Fabbro M; Schmalfeldt B; Hardy-Bessard AC; Runnebaum I; Pujade-Lauraine E; Ray-Coquard I
    Gynecol Oncol; 2022 Feb; 164(2):254-264. PubMed ID: 34952708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Not Available].
    Joly F; Ray-Coquard I
    Bull Cancer; 2021 Dec; 108(9S1):S1-S4. PubMed ID: 34955157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial.
    Pujade-Lauraine E; Brown J; Barnicle A; Wessen J; Lao-Sirieix P; Criscione SW; du Bois A; Lorusso D; Romero I; Petru E; Yoshida H; Vergote I; Colombo N; Hietanen S; Provansal M; Schmalfeldt B; Pignata S; Martín Lorente C; Berton D; Runnebaum IB; Ray-Coquard I
    JCO Precis Oncol; 2023 Jan; 7():e2200258. PubMed ID: 36716415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
    Lee CK; Friedlander ML; Tjokrowidjaja A; Ledermann JA; Coleman RL; Mirza MR; Matulonis UA; Pujade-Lauraine E; Bloomfield R; Goble S; Wang P; Glasspool RM; Scott CL;
    Cancer; 2021 Jul; 127(14):2432-2441. PubMed ID: 33740262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer.
    Arora S; Balasubramaniam S; Zhang H; Berman T; Narayan P; Suzman D; Bloomquist E; Tang S; Gong Y; Sridhara R; Turcu FR; Chatterjee D; Saritas-Yildirim B; Ghosh S; Philip R; Pathak A; Gao JJ; Amiri-Kordestani L; Pazdur R; Beaver JA
    Oncologist; 2021 Jan; 26(1):e164-e172. PubMed ID: 33017510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.
    Bartoletti M; Pelizzari G; Gerratana L; Bortot L; Lombardi D; Nicoloso M; Scalone S; Giorda G; Baldassarre G; Sorio R; Puglisi F
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olaparib: A Review as First-Line Maintenance Therapy in Advanced Ovarian Cancer.
    Paik J
    Target Oncol; 2021 Nov; 16(6):847-856. PubMed ID: 34623572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
    Ray-Coquard I; Pautier P; Pignata S; Pérol D; González-Martín A; Berger R; Fujiwara K; Vergote I; Colombo N; Mäenpää J; Selle F; Sehouli J; Lorusso D; Guerra Alía EM; Reinthaller A; Nagao S; Lefeuvre-Plesse C; Canzler U; Scambia G; Lortholary A; Marmé F; Combe P; de Gregorio N; Rodrigues M; Buderath P; Dubot C; Burges A; You B; Pujade-Lauraine E; Harter P;
    N Engl J Med; 2019 Dec; 381(25):2416-2428. PubMed ID: 31851799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection of maintenance therapy during first-line treatment of advanced ovarian cancer based on pharmacologic characteristics.
    Nakai H; Matsumura N
    Expert Opin Pharmacother; 2023; 24(18):2161-2173. PubMed ID: 38111255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
    Lau CH; Seow KM; Chen KH
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
    Gadducci A; Guarneri V; Peccatori FA; Ronzino G; Scandurra G; Zamagni C; Zola P; Salutari V
    J Ovarian Res; 2019 Jan; 12(1):9. PubMed ID: 30691488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study.
    Colombo N; Gadducci A; Landoni F; Lorusso D; Sabbatini R; Artioli G; Berardi R; Ceccherini R; Cecere SC; Cormio G; De Angelis C; Legge F; Lissoni A; Mammoliti S; Mangili G; Naglieri E; Petrella MC; Ricciardi GRR; Ronzino G; Salutari V; Sambataro D; Savarese A; Scandurra G; Tasca G; Tomao F; Valabrega G; Zavallone L; Pignata S
    Gynecol Oncol; 2023 Aug; 175():182-189. PubMed ID: 37355448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly(ADP-Ribose) Polymerase Inhibitor Inhibition in Ovarian Cancer: A Comprehensive Review.
    Moore KN; Pothuri B
    Cancer J; 2021 Nov-Dec 01; 27(6):432-440. PubMed ID: 34904806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.